Dr  Saad Salem

Dr Saad Salem

Lecturer

School of Biomedical Sciences and Pharmacy

Career Summary

Biography

Dr Saad Salem graduated with a Doctor of Pharmacy (PharmD) degree with a strong clinical focus; he appreciates the importance of understanding the mechanism of action of medicines in order to develop and optimise pharmacotherapeutic plans and make sound clinical judgements. Saad completed a PhD at The University of Melbourne investigating the role of transforming growth factor-beta (TGF-β) in modulating the cellular responses of glucocorticoids, an important class of medicines used to treat asthma and inflammatory conditions.  Dr Salem’s research was awarded multiple prizes including best oral presentation at the Thoracic Society of Australia and New Zealand (TSANZ) annual scientific meeting and Neville Percy prize for best poster presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) annual scientific meeting. He was invited by the British Pharmacological Society (BPS) to present his research at the BPS annual winter scientific meeting in London for which he was awarded a travel grant. He is a member of the translational research program at the Hunter Medical Research Institute (HMRI) focusing on viruses, infections/immunity, vaccines and asthma (VIVA).  

Dr Salem is a pharmacist registered with the Pharmacy Board of Australia and the Australian Health Practitioner Regulation Agency (AHPRA). He incorporates his experience as a community pharmacist into his teaching of pharmacotherapy and pharmacy practice and strives to equip students with the knowledge and skills to become future leaders in pharmacy.


Qualifications

  • Doctor of Philosophy, University of Melbourne
  • Doctor of Pharmacy, Jordan University of Science & Technology - Jordan

Fields of Research

Code Description Percentage
321403 Clinical pharmacy and pharmacy practice 100

Professional Experience

UON Appointment

Title Organisation / Department
Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Awards

Award

Year Award
2020 DVC(A) Educator Innovation and Impact Award
Office of the DVC(A), The University of Newcastle, Australia

Prize

Year Award
2011 The British Pharmacological Society Travel Bursary
The British Pharmacological Society (BPS)
2010 Neville Percy Prize for Best Poster Presentation at The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists
Australian Society of Clinical and Experimental Pharmacologists and Toxicologists
2010 The Thoracic Society of Australia and New Zealand Best Oral Presentation
The Thoracic Society of Australia and New Zealand

Scholarship

Year Award
2011 The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists International Travel Scholarship
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists
2011 The University of Melbourne Abroad Travel Scholarship
The University of Melbourne
2011 M.A. Bartlett Research Scholarship Fund
The University of Melbourne
2011 The Department of Pharmacology, The University of Melbourne Abroad Travelling Scholarship
The University of Melbourne

Invitations

Speaker

Year Title / Rationale
2011 TGF-beta Impairs Glucocorticoid Responses in Airway Epithelial Cells
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (7 outputs)

Year Citation Altmetrics Link
2020 Drovandi A, Salem S, Barker D, Booth D, Kairuz T, 'Human Biomarker Exposure from Cigarettes Versus Novel Heat-Not-Burn Devices: A Systematic Review and Meta-Analysis', Nicotine and Tobacco Research, 22 1077-1085 (2020) [C1]

Introduction: Novel tobacco products require independent research to assess their safety. This study assessed the current literature for trials comparing levels of biomarkers of e... [more]

Introduction: Novel tobacco products require independent research to assess their safety. This study assessed the current literature for trials comparing levels of biomarkers of exposure (BoE) between conventional cigarettes (CC) and heat-not-burn (HNB) devices. Methods: Ten databases were searched using terms including: "heat not burn,""iqos,""teeps,""mrtp,""tobacco heating,"and "glo"between January 1, 2010 and August 13, 2019. Randomized controlled trials (RCTs) assessing comparative BoE levels in humans using either CC or novel HNB devices were eligible. BoE were tabulated, and differences between the intervention and control groups were analyzed and combined using a random-effects meta-analysis. Results: Ten nonblinded, RCTs were eligible, involving a total of 1766 participants. Studies regularly reported on 12 BoE (including nicotine). HNB devices assessed included the "IQOS"and "glo"devices and "precursor"(being developed) HNB devices. In comparison to CC, all 12 BoEs assessed were significantly lower for participants assigned to an HNB device. In comparison to smoking abstinence, HNB devices were statistically equivalent for eight BoEs and significantly elevated for four BoEs. Conclusions: This review found that the potential for harm to humans is reduced when using HNB devices compared to CC as indicated by significant reductions in BoE levels. Whilst these results support tobacco manufacturer claims of improved safety, the small number of studies included, limited range of BoE assessed, and involvement of the tobacco industry necessitate further independent research to confirm the HNB devices as being a safer alternative to CC. Implications: This study supports claims made by tobacco manufacturers on the improved safety of HNB tobacco devices in comparison to CC. These novel devices lead to reduced exposure to key biomarkers, which are linked to the health consequences attributed to tobacco use. This has strong implications for international public health as well as further research and policy development relating to the safety aspects and legalities of novel tobacco products.

DOI 10.1093/ntr/ntz200
Citations Scopus - 15Web of Science - 16
Co-authors Therese Kairuz, Daniel Barker, Debbie Booth
2020 Salem S, Cooper J, Schneider J, Croft H, Munro I, 'Student Acceptance of Using Augmented Reality Applications for Learning in Pharmacy: A Pilot Study.', Pharmacy (Basel, Switzerland), 8 1-10 (2020) [C1]
DOI 10.3390/pharmacy8030122
Citations Web of Science - 8
Co-authors Hayley Croft, Joyce Cooper, Jennifer Schneider
2020 Schneider J, Patfield M, Croft H, Salem S, Munro I, 'Introducing Augmented Reality Technology to Enhance Learning in Pharmacy Education: A Pilot Study.', Pharmacy (Basel, Switzerland), 8 (2020) [C1]
DOI 10.3390/pharmacy8030109
Citations Web of Science - 5
Co-authors Hayley Croft, Jennifer Schneider
2014 Keenan CR, Mok JSL, Harris T, Xia Y, Salem S, Stewart AG, 'Bronchial epithelial cells are rendered insensitive to glucocorticoid transactivation by transforming growth factor-ß1', Respiratory Research, 15 (2014) [C1]

Background: We have previously shown that transforming growth factor-beta (TGF-beta) impairs glucocorticoid (GC) function in pulmonary epithelial cell-lines. However, the signalli... [more]

Background: We have previously shown that transforming growth factor-beta (TGF-beta) impairs glucocorticoid (GC) function in pulmonary epithelial cell-lines. However, the signalling cascade leading to this impairment is unknown. In the present study, we provide the first evidence that TGF-beta impairs GC action in differentiated primary air-liquid interface (ALI) human bronchial epithelial cells (HBECs). Using the BEAS-2B bronchial epithelial cell line, we also present a systematic examination of the known pathways activated by TGF-beta, in order to ascertain the molecular mechanism through which TGF-beta impairs epithelial GC action.Methods: GC transactivation was measured using a Glucocorticoid Response Element (GRE)-Secreted embryonic alkaline phosphatase (SEAP) reporter and measuring GC-inducible gene expression by qRT-PCR. GC transrepression was measured by examining GC regulation of pro-inflammatory mediators. TGF-beta signalling pathways were investigated using siRNA and small molecule kinase inhibitors. GRa level, phosphorylation and sub-cellular localisation were determined by western blotting, immunocytochemistry and localisation of GRa-Yellow Fluorescent Protein (YFP). Data are presented as the mean ± SEM for n independent experiments in cell lines, or for experiments on primary HBEC cells from n individual donors. All data were statistically analysed using GraphPad Prism 5.0 (Graphpad, San Diego, CA). In most cases, two-way analyses of variance (ANOVA) with Bonferroni post-hoc tests were used to analyse the data. In all cases, P <0.05 was considered to be statistically significant.Results: TGF-beta impaired Glucocorticoid Response Element (GRE) activation and the GC induction of several anti-inflammatory genes, but did not broadly impair the regulation of pro-inflammatory gene expression in A549 and BEAS-2B cell lines. TGF-beta-impairment of GC transactivation was also observed in differentiated primary HBECs. The TGF-beta receptor (ALK5) inhibitor SB431541 fully prevented the GC transactivation impairment in the BEAS-2B cell line. However, neither inhibitors of the known downstream non-canonical signalling pathways, nor knocking down Smad4 by siRNA prevented the TGF-beta impairment of GC activity.Conclusions: Our results indicate that TGF-beta profoundly impairs GC transactivation in bronchial epithelial cells through activating ALK5, but not through known non-canonical pathways, nor through Smad4-dependent signalling, suggesting that TGF-beta may impair GC action through a novel non-canonical signalling mechanism. © 2014 Keenan et al.; licensee BioMed Central Ltd.

DOI 10.1186/1465-9921-15-55
Citations Scopus - 25Web of Science - 29
2012 Salem S, Harris T, Mok JSL, Li MYS, Keenan CR, Schuliga MJ, Stewart AG, 'Transforming growth factor-ß impairs glucocorticoid activity in the A549 lung adenocarcinoma cell line', British Journal of Pharmacology, 166 2036-2048 (2012) [C1]
DOI 10.1111/j.1476-5381.2012.01885.x
Citations Scopus - 40Web of Science - 41
Co-authors Michael Schuliga
2012 Keenan CR, Salem S, Fietz ER, Gualano RC, Stewart AG, 'Glucocorticoid-resistant asthma and novel anti-inflammatory drugs', Drug Discovery Today, 17 1031-1038 (2012) [C1]
DOI 10.1016/j.drudis.2012.05.011
Citations Scopus - 51Web of Science - 47
2009 Alzoubi KH, Mhaidat N, Al Azzam S, Khader Y, Salem S, Issaifan H, Haddadin R, 'Prevalence of migraine and tension-type headache among adults in Jordan', JOURNAL OF HEADACHE AND PAIN, 10 265-270 (2009)
DOI 10.1007/s10194-009-0122-6
Citations Scopus - 21Web of Science - 12
Show 4 more journal articles

Conference (5 outputs)

Year Citation Altmetrics Link
2013 Keenan C, Lopez-Campos G, Salem S, Harris T, Schuliga M, Johnstone C, Stewart A, 'RNA-seq analysis of transforming growth factor-beta-induced glucocorticoid resistance in human bronchial epithelial cells', EUROPEAN RESPIRATORY JOURNAL (2013)
Co-authors Michael Schuliga
2013 Keenan CR, Salem S, Harris T, Schuliga M, Stewart AG, 'TRANSFORMING GROWTH FACTOR-beta INDUCES GLUCOCORTICOID RESISTANCE IN HUMAN BRONCHIAL EPITHELIAL CELLS', RESPIROLOGY (2013)
Co-authors Michael Schuliga
2011 Salem S, Harris T, Schuliga M, Mok J, Stewart A, 'Transforming Growth Factor Beta (TGFBeta) Induces Glucocorticoid-Resistance In A549 Adenocarcinoma Cell Line By Reducing Glucocorticoid Receptor Nuclear Localisation', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Co-authors Michael Schuliga
2010 Stewart A, Salem S, Lian JMS, Schuliga M, Harris T, 'Glucocorticoid resistance in human airway epithelial cells: a potential role for Transforming Growth Factor-beta', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Co-authors Michael Schuliga
2009 Stewart AG, Schuliga M, Mok J, Salem S, Harris T, 'TGF-Induces Glucocorticoid Resistance beta.', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Co-authors Michael Schuliga
Show 2 more conferences
Edit

Grants and Funding

Summary

Number of grants 4
Total funding $18,400

Click on a grant title below to expand the full details for that specific grant.


20191 grants / $2,500

Simulation Technology in Pharmacy Learning$2,500

Funding body: the Educator Network (tEN)

Funding body the Educator Network (tEN)
Project Team

Irene Munro, Saad Salem, Joyce Cooper, David Newby, Hayley Croft and Hennifer Schneider

Scheme Teaching and Innovation Investment Scheme (TI2)
Role Investigator
Funding Start 2019
Funding Finish 2019
GNo
Type Of Funding Internal
Category INTE
UON N

20183 grants / $15,900

Assessment Algorithm for Pharmaceutical Dispensing and Medication Counselling$8,000

Funding body: Faculty of Health and Medicine, The University of Newcastle

Funding body Faculty of Health and Medicine, The University of Newcastle
Project Team

Therese Kairuz, Saad Salem, Joyce Cooper, Angela Hawke and Pari Efekthari

Scheme UON Faculty of Health and Medicine Pilot Scheme
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N

Development of Augmented Reality (AR) and Virtual Reality (VR) Applications to Enhance Learning in Pharmacy$4,000

Funding body: Faculty of Health and Medicine, The University of Newcastle

Funding body Faculty of Health and Medicine, The University of Newcastle
Project Team

Saad Salem, Irene Munroe, Hayley Croft and Jennifer Schneider

Scheme UON Faculty of Health and Medicine Pilot Scheme
Role Lead
Funding Start 2018
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N

Let's Talk About Sex$3,900

Funding was provided to establish a series of pop-up clinics operated by pharmacy students from the University of Newcastle to educate students and the general public about sexual health and well being.

Funding body: the Educator Network (tEN)

Funding body the Educator Network (tEN)
Project Team

Karen Mate and Saad Salem

Scheme Teaching and Innovation Investment Scheme (TI2)
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Dr Saad Salem

Position

Lecturer
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Contact Details

Email saad.salem@newcastle.edu.au
Phone (02) 4985 4380

Office

Room MS116
Building Medical Science Building
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit